LTI-03 is under clinical development by Aileron Therapeutics and currently in Phase I for Idiopathic Pulmonary Fibrosis. According to GlobalData, Phase I drugs for Idiopathic Pulmonary Fibrosis have a 66% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how LTI-03’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
LTI-03 overview
LTI-03 is under development for the treatment of idiopathic pulmonary fibrosis. The drug candidate is a caveolin-1 scaffolding domain 7-mer peptide (FTTFTVT). It is administered through inhalational route.
Aileron Therapeutics overview
Aileron Therapeutics is a biopharmaceutical company. The company develops medicines to make chemotherapy safer and thereby more effective to save more patients’ lives. Its products include ALRN-6924 MDM2 and MDMX dual inhibitor a chemoprotective agent that treats patients with p53-mutated cancers. It also provides radioprotection, anti-cancer research and discovery research. The company partners with research organizations to provide its products. Aileron Therapeutics is headquartered in Boston, Massachusetts, the US.
For a complete picture of LTI-03’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
